PDF herunterladen
Semin Neurol 2002; 22(1): 071-074
DOI: 10.1055/s-2002-33050
Copyright © 2002 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.: +1(212) 584-4662

The Treatment of Alzheimer's Disease: The Approach from a Clinical Specialist in the Trenches

Ann Marie Hake
  • Clinical Assistant Professor, Department of Neurology, Indiana University School of Medicine, Indianapolis, Indiana
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
12. August 2002 (online)

    Lizenzen und Reprints

ABSTRACT

Alzheimer's disease (AD) is the most common form of dementia, and its incidence increases with age. Treatment with cholinesterase inhibitor drugs is currently the standard of care. Several other medications and nonpharmacologic therapies are also available for the treatment of cognitive decline and other symptoms of AD. This article reviews the current recommendations for the treatment of Alzheimer's disease.

KEYWORDS

Alzheimer's disease - dementia - cholinesterase inhibitors - therapy

REFERENCES

  • 1 Katzman R. Epidemiology of Alzheimer's disease.  Neurobiol Aging . 2000;  S1
    PubMedGoogle Scholar
  • 2 Kokmen E, Beard C M, O'Brien P C, Kurland L T. Epidemiology of dementia in Rochester, Minnesota.  Mayo Clin Proc . 1996;  71 275-282
    CrossrefPubMedGoogle Scholar
  • 3 Brookmeyer R, Gray S, Kawas C. Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset.  Am J Public Health . 1998;  88 1337-1342
    CrossrefPubMedGoogle Scholar
  • 4 Davies P, Maloney A J. Selective loss of central cholinergic neurons in Alzheimer's disease.  Lancet . 1976;  2 1403
    PubMedGoogle Scholar
  • 5 Rogers S L, Farlow M R, Doody R S, Mohs R, Friedhoff L T. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group.  Neurology . 1998;  50 136-145
    CrossrefPubMedGoogle Scholar
  • 6 Burns A, Rossor M, Hecker J. The effects of donepezil in Alzheimer's disease: results from a multinational trial.  Dement Geriatr Cogn Disord . 1999;  10 237-244
    CrossrefPubMedGoogle Scholar
  • 7 Rosler M, Anand R, Cicin-Sain A. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial.  BMJ . 1999;  318 633-638
    PubMedGoogle Scholar
  • 8 Tariot P N, Solomon P R, Morris J C. A 5-month, randomized, placebo-controlled trial of galantamine in AD.  Neurology . 2000;  54 2269-2276
    PubMedGoogle Scholar
  • 9 Raskind M A, Peskind E R, Wessel T, Yuan W, and the Galantamine USA-1 Study Group. Galantamine in AD. A 6-month randomized, placebo-controlled trial with a 6-month extension.  Neurology . 2000;  54 2261-2268
    PubMedGoogle Scholar
  • 10 Hake A M, Farlow M R. New concepts in the drug therapy of Alzheimer's disease.  Expert Opinion on Pharmacotherapy . 2001;  2 1975-1983
    CrossrefPubMedGoogle Scholar
  • 11 Farlow M, Anand R, Messina Jr J, Hartman R, Veach J. A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer's disease.  Eur Neurol . 2000;  44 236-241
    CrossrefPubMedGoogle Scholar
  • 12 Doody R S, Geldmacher D S, Gordon B. Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer's disease.  Arch Neurol . 2001;  58 427-433
    CrossrefPubMedGoogle Scholar
  • 13 Rogers S L, Doody R S, Pratt R D, Ieni J R. Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: final analysis of a US multicentre open-label study.  Eur Neuropsychopharmacology . 2000;  10 195-203
    PubMedGoogle Scholar
  • 14 Feldman H, Gauthier S, Hecker J, Vellas B, Subbiah P, Whalen E. Benefits of donepezil on global function, behavior, cognition, and ADLs in patients with moderate-to-severe Alzheimer's disease.  Neurology . 2000;  A469
    PubMedGoogle Scholar
  • 15 Cummings J, Anand R, Koumaras B, Harman R. Rivastigmine provides behavioral benefits to Alzheimer's disease patients residing in a nursing home: findings from a 26-week trial.  Neurology . 2000;  A468-A469
    PubMedGoogle Scholar
  • 16 Feldman H, Gauthier S, Hecker J, Vellas B, Subbiah P, Whalen E. Donepezil MSAD Study Investigators Group. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease.  Neurology . 2001;  57 613-620
    CrossrefPubMedGoogle Scholar
  • 17 Newmann J P. Aging and depression.  Psychol Aging . 1989;  4 150-165
    PubMedGoogle Scholar
  • 18 Lazarus L W, Newton N, Cohler B, Lesser J, Schweon C. Frequency and presentation of depressive symptoms in patients with primary degenerative dementia.  Am J Psychiatry . 1987;  144 41-45
    PubMedGoogle Scholar
  • 19 Karlsson I. Treatment of non-cognitive symptoms in dementia.  Acta Neurologica Scandinavica Supplementum . 1996;  168 93-95
    PubMedGoogle Scholar
  • 20 Katz I R, Jeste D V, Mintzer J E, Clyde C, Napolitano J, Brecher M. Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial.  J Clin Psychiatry . 1999;  60 107-115
    PubMedGoogle Scholar
  • 21 Street J S, Clark W S, Gannon K S. Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial: The HGEU Study Group.  Arch Gen Psychiatry . 2000;  57 968-976
    PubMedGoogle Scholar
  • 22 McKeith I, Fairbairn A, Perry R, Thompson P, Perry E. Neuroleptic sensitivity in patients with senile dementia of Lewy body type.  BMJ . 1992;  305 673-678
    CrossrefPubMedGoogle Scholar
  • 23 Rojas-Fernandez C H. Successful use of donepezil for the treatment of dementia with Lewy bodies.  Ann Pharmacother . 2001;  35 202-205
    CrossrefPubMedGoogle Scholar
  • 24 McKeith I, Del Ser T, Spano P. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study.  Lancet . 2000;  356 2031-2036
    CrossrefPubMedGoogle Scholar
  • 25 Sutor B, Rummans T A, Smith G E. Assessment and management of behavioral disturbances in nursing home patients with dementia.  Mayo Clin Proc . 2001;  76 540-550
    PubMedGoogle Scholar
  • 26 Sano M, Ernesto C, Thomas R G. A controlled trial of selegiline, alpha-tocopherol or both as treatment for Alzheimer's disease.  N Engl J Med . 1997;  336 1216-1222
    PubMedGoogle Scholar
  • 27 Cheung M C, Zhao X Q, Chait A, Albers J J, Brown B G. Antioxidant supplements block the response of HDL to simvastatin-niacin therapy in patients with coronary artery disease and low HDL.  Arterioscler Thromb Vasc Biol . 2001;  21 1320-1326
    PubMedGoogle Scholar